Pharmaceutical manufacturers looking to help patients gain access to expensive drug and medical treatments need to review and follow guidance from the Department of Health and Human Services’ Office of Inspector General (OIG). OIG for decades has provided guidance to providers and pharmacies about waiving patients’ cost-sharing obligations, and this provides a good foundation for the government’s view on copays and deductibles, said Matthew Wetzel, the former associate general counsel and chief compliance officer for Grail Inc. and now a partner in the Healthcare and Life Sciences division at Goodwin. Read the Specialty Pharma Continuum article here.